Sigma Systems Accelerates Product and Service Innovation for Hong Kong’s SmarTone
Sigma Systems, the global leader in catalog-driven software, today announces that it has been selected by SmarTone, a leading telecommunications provider with operating subsidiaries in Hong Kong and Macau, to accelerate its digital transformation and time-to-market for new products and offerings for its two million-plus customers.
Under this multi-year agreement, Sigma Systems will deploy Sigma Catalog, Sigma CPQ, Sigma Order Management, Sigma Portfolio Inventory and Sigma Insights, which constitute its award-winning Create-Sell-Deliver Portfolio. This will accelerate product and service innovation for SmarTone, expedite service delivery to customers and play a central role in supporting the service provider’s 5G-focused strategy. The implementation will be carried out in partnership with Hong Kong-headquartered WiseSpot, a leading systems integrator and solutions developer for the telecommunications industry.
Stephen Chau, Chief Technology Officer, SmarTone, commented: “Service excellence has always been our forte in setting us apart from our competition. At SmarTone, we strive to provide customers with an optimal user experience by continuously investing to improve our dynamic blend of key technologies and fine skills. With the advent of 5G, enhancing our core capability to more rapidly innovate around services will be vital in introducing new applications on IoT, mobile connectivity, edge computing and highly immersive, interactive experiences. By partnering with Sigma Systems, we will be better equipped to continue building our strength and serve our customers as their preferred service provider, as we look to roll out a new range products and services in line with our vision for a 5G future.”
Tim Spencer, Chief Executive Officer, Sigma Systems, commented: “In the age of digital services and 5G, driving product innovation and capitalizing upon new revenues is an imperative for CSPs. Today’s service providers need to create, sell and deliver services in a frictionless, automated and error-free way. At Sigma Systems, our strength lies in helping service providers successfully navigate complexities inherent in the current landscape and transform their businesses to accelerate product innovation – and get Next Done NowTM. This agreement with SmarTone is testament to the value that Sigma Systems’ Create-Sell-Deliver portfolio brings to any service provider and we are confident that with our unique offering, they will be able to launch new products and services seamlessly, and thus cater effectively to a new generation of consumers.”
For further information about Sigma Systems, its award-winning Create-Sell-Deliver portfolio, and getting Next Done NowTM visit sigma-systems.com, or contact us on info@sigma-systems.com.
About Sigma Systems (Twitter @SigmaSystems)
Sigma Systems is the global leader in catalog-driven software solutions for telecommunications, media and high-tech companies. It serves over 80 customers in 40 countries with its award-winning products. The company’s portfolio spans enterprise-wide Catalog, Configure Price Quote (CPQ), Order Management, Provisioning, Insights and Portfolio Inventory products, and offers a core set of services including professional services, cloud services, and managed services. Sigma utilizes an agile approach to implementing its B/OSS products for its customers. Sigma has offices in North and South America, Europe and the Asia Pacific region, with technology and integration partners around the globe. Sigma is a Hansen Technologies company publicly listed on the Australian Stock Exchange – ASX:HSN.
Additional information can be found online at https://sigma-systems.com/.
Visit Hansen Technologies at https://www.hansencx.com/.
About SmarTone
SmarTone Telecommunications Holdings Limited (0315.HK) is a leading telecommunications company with operating subsidiaries in Hong Kong and Macau, providing voice, multimedia and mobile broadband services, as well as fixed fibre broadband services for the consumer and corporate markets. Its goal is to deliver unbeatable and valuable experiences to customers through its powerful network, purposeful apps and passionate service. The company has been listed in Hong Kong since 1996. It is a subsidiary of Sun Hung Kai Properties Limited (0016.HK).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191103005007/en/
Contact information
Adnan Bashir
Senior Corporate Communications Manager
Sigma Systems
+1 647-204-0999
Chloe Purcell
Head of PR
Milner Strategic Marketing Ltd.
+44 1473 633123
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA ® Commercialization in Central and Eastern Europe7.1.2026 09:30:00 EET | Press release
Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnosed FLT3-ITD positive AML in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as maintenance monotherap
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom